Epidermal growth factor receptor tyrosine kinase inhibitors by Ranson, M
Minireview
Epidermal growth factor receptor tyrosine kinase inhibitors
M Ranson*,1
1Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
Activation of the epidermal growth factor receptor (EGFR) has been linked to tumour proliferation, invasion, metastasis and
angiogenesis in epithelial tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches
have been developed, humanised monoclonal antibodies and tyrosine kinase inhibitors. This review discusses the current status of
EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have entered clinical development. EGFR-TKIs are generally well tolerated and can
sometimes produce impressive tumour regression in patients with advanced non-small-cell lung cancer. However, highly predictive or
surrogate markers of activity have not been identified and there remains a need for translational research in their future development.
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Trans-membrane receptor tyrosine kinases play an important role
in the modulation of growth factor signalling. The epidermal
growth factor receptor (EGFR) is a member of a family of four
closely related receptors: EGFR (or erbB1), HER2/neu (erbB2),
HER3 (erbB3) and HER4 (erbB4). The EGFR mediates the actions
of multiple ligands including epidermal growth factor, transform-
ing growth factor-a, amphiregulin and heparin-binding EGF, and
may also be constitutively activated by mutation. EGFR signalling
has been reported to be important for tumour cell proliferation,
inhibition of apoptosis, angiogenesis, metastasis and sensitivity to
chemotherapy and radiotherapy (Ritter and Arteaga, 2003;
Arteaga, 2003a). EGFR signalling is also important in normal
epithelial cell biology and thus defining a therapeutic window for
EGFR inhibitors has been an important goal in their clinical
evaluation. EGFR signalling is complex. Homodimerisation and
heterodimerisation with other EGFR family members is known to
occur (Jorissen et al, 2003). Within the EGFR family, HER2
appears to be a preferred heterodimer partner.
The quinazolines, gefitinib and erlotinib, which are the most
advanced in clinical development, are competitive inhibitors at the
tyrosine kinase ATP binding site. Irreversible inhibitors that bind
to specific cysteines in the ATP-binding pocket of EGFR family
receptors have been developed. Examples include CI-1033 and
EKB-569. The structural homology between EGFR receptor
members has also been exploited for the development of inhibitors
that block multiple members of the EGFR family (Table 1).
PHARMACODYNAMICS
All the EGFR TKIs shown in Table 1 act at the ATP binding site in
the catalytic domain of the receptor and in vitro inhibit EGFR
tyrosine kinase at low nanomolar concentrations. A key finding is
a lack of a close correlation between varying degrees of EGFR
expression in tumour cells and their sensitivity to EGFR TKI
inhibitors such that low-level EGFR tumours can be more sensitive
than tumours with high receptor expression (Parra et al, 2002;
Ciardiello et al, 2003).
Research in breast and other epithelial cell lines has suggested
that HER-2 overexpressing tumours may be more sensitive to
EGFR inhibitors such as gefitinib (Moasser et al, 2001). Others
have reported that gefitinib can block HER-2 function by inducing
the formation of inactive unphosphorylated EGFR/HER2 and
EGFR/HER3 heterodimers and by blocking the formation of HER2/
HER3 heterodimers (Anido et al, 2003). In cells that co-express
HER2 and EGFR, ligand activation preferentially recruits HER2
into a heterodimeric complex that has increased stability and a
different endocytic recycling, resulting in increased signalling
potency (Lenferink et al, 1998). Such results suggest that EGFR
TKIs should be tested in patients with EGFRþHER-2-positive
breast cancer. However, it should be noted that the clinical activity
of gefitinib has recently been reported to be unaffected by HER2
status in a small-scale trial in advanced non-small-cell lung cancer
(NSCLC) (Cappuzzo et al, 2003).
The downstream molecular mechanisms underlying the anti-
tumour actions of EGFR TKIs have been examined in preclinical
models, with particular attention on mitogen-activated protein
kinase (MAP kinase) and phosphatidylinositol 30–kinase/Akt (PI3/
Akt) pathways. In A431 cells, the antitumour effects of gefitinib are
mediated via inhibition of both MAP kinase and PI3/Akt pathways
resulting in apoptotic cell death. In NSCLC cell lines, however,
more limited antiproliferative effects were accompanied by
evidence of continued activity in one or both of these pathways
(Janmaat et al, 2003). Early attempts to define mechanisms of
resistance to TKIs suggests that the PI3/Akt pathway is important
as a loss of PTEN, allowing high levels of Akt independent of EGFR
control, blocks the effects of EGFR inhibitors, and persistent Akt
activity is seen in resistant cells (Bianco et al, 2003; She et al, 2003).
Mechanistic information has also emerged from pharmacody-
namic studies performed during early clinical trials. In a phase I/II
pharmacodynamic trial in patients with metastatic colorectal
cancer, gefitinib produced loss of immunohistochemical staining
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in some but by no means all tumour biopsies (Daneshmand et al,
2003). Pharmacodynamic studies of skin biopsies before and
during gefitinib therapy showed that doses well below the maximal
tolerated dose (MTD) inhibited MAP kinase activation, increased
p27 expression and reduced keratinocyte proliferation (Albanell
et al, 2002). Using Erlotinib and monitoring EGFR signalling in
skin biopsies, significant decreases in activated EGFR expression
and increased expression of p27 as assessed by immunohisto-
chemistry have been reported, but no significant effect was seen in
phospho-ERK expression (Malik et al, 2003).
Attempts have been made to identify tumour phenotypic and
genotypic profiles that confer sensitivity to EGFR TKIs (Perez-
Soler et al, 2003). To identify genes that might be associated with
sensitivity to gefitinib, a detailed expression profiling from a panel
of human xenograft tumours has been undertaken (Zembutsu et al,
2003). An analysis of over 23000 genes revealed 114 genes whose
expression correlated significantly with sensitivity to gefitinib.
These preclinical data need to be compared with preliminary data
emerging from clinical trial tumour specimens (Natale et al, 2003).
GEFITINIB AND ERLOTINIB
Gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva) are in
advanced phase II/III development and other agents are in phase I/
II trials Table 1. Gefitinib is currently licensed for use in relapsed
advanced NSCLC in Japan, Australia and USA and applications are
underway in other territories. Both agents have good oral
bioavailability and are suitable for once daily administration. In
phase I trials, skin rash and diarrhoea are dose limiting. Gefitinib
appears to be active below its MTD. Evidence of therapeutic
activity of gefitinib was seen at doses as low as 150mgday
 1 in
patients with relapsed advanced NSCLC with anecdotal activity in
other tumours (Baselga et al, 2002; Herbst et al, 2002; Ranson et al,
2002; Nakagawa et al, 2003). The MTD in these phase I trials was
600–1000mgday
 1. Multicentre phase II trials in patients with
relapsed NSCLC after chemotherapy have confirmed that gefitinib
and erlotinib have activity in this setting with partial response
rates of around 15% (Perez-Soler et al, 2001; Kris et al, 2002;
Fukuoka et al, 2003) (Table 2).
In a randomised trial of gefitinib 250mgday
 1 vs 500mgday
 1
in second or third line treatment of relapsed, advanced stage
NSCLC (IDEAL 1 trial), the median survival of 210 randomised
patients from the start of ZD1839 was 7.8 months with a median
survival in responding patients of approximately 11 months
(Fukuoka et al, 2003). In this study and a similar trial (IDEAL 2) in
more heavily pretreated symptomatic NSCLC patients (Kris et al,
2002), about a third of patients reported improvement in lung
cancer symptoms assessed by the FACT-L QOL instrument
(Natale and Zaretsky, 2002). Very similar activity has been
reported for erlotinib dosed at its MTD of 150mgday
 1 in a single
arm phase II trial in 56 evaluable patients (Perez-Soler et al, 2001).
Erlotinib and gefitinib have been studied in phase II trials in
patients with advanced squamous cell carcinoma of the head and
neck (SCCHN). Response rates of approximately 5–10% have been
reported with up to a third of patients showing stable disease
(Cohen et al, 2003; Herbst, 2003). A phase II trial of gefitinib
500mgday
 1 in 52 patients with recurrent SCCHN showed a
response rate of 10.6%. Survival in trials of EGFR TKIs in relapsed
SCCHN are similar to those seen with other agents in this patient
cohort, and randomised trials are now required.
Since antitumour activity has been seen below the MTD for
gefitinib, defining an optimal dose of EGFR TKI may need to be
based on an appraisal of other end points. The phase I trials of
gefitinib were unusual in using expanded dosing cohorts so as to
provide early opportunity for investigation of end points other
than simply the MTD. Over 250 patients were enrolled in four
Phase I trials of gefitinib, including 100 patients with relapsed
advanced NSCLC (Baselga et al, 2002; Herbst et al, 2002; Ranson
et al, 2002; Nakagawa et al, 2003). Partial responses in NSCLC were
seen across a wide dose range (150–1000mgday
 1), and
pharmacodynamic data showed that EGFR signalling was con-
sistently inhibited in skin biopsies at all doses above 150mgday
 1
(Albanell et al, 2002). Dose levels of X150mgday
 1 also achieved
plasma levels, which were markedly inhibitory (above IC90 values)
Table 1 EGFR TKIs in clinical development
Drug Other names Description Status
Gefitinib ZD1839, Iressa Quinazoline, reversible, EGFR TKI Phase II/III, launched Japan, Australia, USA
Erlotinib OSI-774, Tarceva Quinazoline, reversible, EGFR TKI Phase II/III
PKI-166 CGP59326 Pyrrolo-pyrimidine, reversible, dual EGFR/erbB2 TKI Phase I/II
GW-572016 GW-2016 Thio-quinazoline, reversible, dual EGFR/erbB2 TKI Phase I/II
Canertinib CI-1033, PD-0183805 Pyrido-pyrimidine, irreversible, Pan-erbB TK1 Phase II
EKB-569 Cyanoquinoline, irreversible, dual EGFR/erbB2 TKI Phase I/II
ZD6474 Quinazoline, reversible, VEGFR/flk-1/KDR/EGFR TKI Phase II
Table 2 Summary of phase II trials of gefitinib and erlotinib monotherapy in relapsed advanced NSCLC
Drug
Number of
evaluable
patients
Number of prior
chemotherapy
regimens Dosing
Response
rate (%)
Response+stable
disease
Median survival
a
(months) Reference
Gefitinib 209 1 or 2 (platinum,
docetaxel containing)
250mgday
 1 vs
500mgday
 1
18.4 54.4 7.6 Fukuoka et al (2003)
IDEAL 1
Gefitinib 216 At least 2 including both
platinum and docetaxel
250mgday
 1 vs
500mgday
 1
11.8 42.2 6.5 Kris et al (2002)
IDEAL 2
Erlotinib 56 At least 1 including
platinum
150mgday
 1 12.3 39.0 8.5 Perez-Soler et al (2001)
aSurvival from the start of EGFR TKI.
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appraisal, two randomised phase II studies of gefitinib comparing
250mg vs 500mgday
 1 in over 400 patients with relapsed NSCLC
were conducted (Kris et al, 2002; Fukuoka et al, 2003) Both these
trials showed greater toxicity (mainly rash and diarrhoea), with no
additional therapeutic benefit from the higher dose. From these
data, the conclusion can be drawn that for relapsed NSCLC, the
optimal dose of gefitinib is 250mgday
 1, which is well below its
MTD.
The approach taken with erlotinib has been quite different.
Phase II and III studies have been conducted at the MTD dose of
150mgday
 1. Whether lower doses of erlotinib would be as
effective as dosing at the MTD is currently unknown. Randomised
trials with sufficient power to detect differences in efficacy would
be needed to address this question. Analysis of data from a small
study of 57 NSCLC patients treated with erlotinib in a phase II trial
showed a significant positive correlation between skin rash and
survival (Herbst, 2003), an observation that deserves to be
examined in randomised dose comparator trials. Patients who
are deriving therapeutic benefit are intrinsically more likely to
have greater periods of drug exposure and thereby may have
increased tendency to rash. To attempt to clarify whether dosing to
MTD is required for erlotinib, a trial is being conducted to dose
patients so as to achieve tolerable rash. It will be important to
determine if this approach for erlotinib yields enhanced survival
and clinical benefit.
Preclinical data have shown that the addition of EGFR TKIs (or
anti-EGFR antibodies) enhances the activity of single agent
cytotoxic drugs (reviewed Arteaga, 2003b). Such observations
fuelled an expectation that the addition of gefitinib to cytotoxic
chemotherapy regimens would result in improved efficacy.
Randomised phase III trials involving over 2000 patients with
stage III/IV NSCLC have been completed to test whether the
addition of gefitinib to doublet chemotherapy improves survival.
Two trials have been reported one with carboplatin/paclitaxel
(INTACT 1), the other with cisplatin/gemcitabine (INTACT 2).
Both studies clearly demonstrated that the addition of gefitinib (at
either 250 or 500mgday
 1) did not improve the response rates,
time to progression or survival compared to combination
chemotherapy alone (Giaccone et al, 2004, Herbst et al, 2004).
Indeed, historically, there has been no convincing evidence that
triplet drug regimens are superior to optimised doublets in
advanced NSCLC.
Randomised phase III trials of erlotinib in combination with
carboplatin/paclitaxel (TRIBUTE TRIAL) or with cisplatin/gemci-
tabine (TALENT TRIAL) have completed patient recruitment, and
in October 2003 OSI Pharmaceuticals announced that these trials
were also negative and that the addition of erlotinib to these
doublet chemotherapy regimens failed to produce a survival
advantage over chemotherapy alone. An important unanswered
question is whether either of these agents improves the efficacy of
single agent chemotherapy. Phase II/III studies of gefitinib or
erlotinib are underway in a wide range of solid tumours including
head and neck cancer, prostate, breast, colorectal, ovarian,
cervical, endometrial, pancreatic, glioblastoma and renal tumours
and preliminary results have been reported in recent reviews
(Herbst, 2003; Schiller, 2003).
The toxicity profile of gefitinib and erlotinib are remarkably
similar; skin rash and diarrhoea being the most frequently
encountered adverse effects. At current phase II/III dose levels,
toxicity is usually grade 1 or 2 and rarely dose limiting. Diarrhoea
usually responds well to antidiarrhoeal treatment; and it has been
observed that skin toxicity can sometimes improve in the face of
continued dosing (Ranson et al, 2002). The incidence of grade III/
IV toxicity with gefitinib monotherapy was 8.7% in IDEAL 1 and
6.9% of patients in IDEAL 2. For monotherapy with erlotinib grade
III/IV adverse events were reported in 30% of patients (Perez-Soler
et al, 2001).
Shortly following the licensing of gefitinib in Japan in 2002,
sporadic reports appeared of interstitial lung disease during
gefitinib therapy (Ieki et al, 2003). The syndrome comprises an
acute onset of bilateral pulmonary infiltrates accompanied by
hypoxia. Some cases have proved fatal while others have improved
following gefitinib withdrawal, steroids and supportive measures.
The incidence in Japan has been reported at 1.7% (Inoue et al,
2003). This is higher than that reported worldwide of 1% in over
92000 patients and of 0.38% in 439000 patients as part of the
compassionate use programme (Forsythe and Faulkner, 2003).
Analysis of the data from the placebo controlled INTACT trials has
been reported to show no difference in incidence of toxicities
which could be included as interstitial lung disease. The
mechanism of gefitinib-related interstitial lung disease is currently
unclear.
OTHER EGFR TKIs
CI-1033, PKI-166, EKB-569 and GW-572016, which produce
inhibition of multiple EGFR family members, are in early phase
clinical development. It will be important to clarify if these wider
spectrum inhibitors have greater therapeutic potential than the
specific EGFR1 TKIs.
Canertinib (CI-1033, PD-0183805)
Canertinib, a water-soluble pyrido-pyrimidine under development
by Pfizer, is a potent kinase inhibitor of all members of the erbB
receptor family. Canertinib produces rapid, irreversible inhibition
of EGFR kinase with an IC50 in the low nanomolar range and
antitumour activity in EGFR and erbB2 dependent preclinical
models (Slichenmyer et al, 2001). Like other EGFR TKIs it inhibits
downstream signalling in both MAP kinase and PI3 kinase/Akt
pathways. Phase I trials have been reported with canertinib using
four different dosing schedules (Rinehart et al, 2002). On a 14-day
schedule every 3 weeks, the MTD was 450mgday
 1 (Nemunaitis
et al, 2003); the MTD was 250mgday
 1 on a 7-day on/7-day off
schedule (Rowinsky et al, 2003), and 150mgday
 1 with contin-
uous dosing (Rinehart et al, 2003). The drug is generally well
tolerated, the most frequent adverse events being diarrhoea, skin
rash and stomatitis (Rinehart et al, 2002; Nemunaitis et al, 2003;
Rowinsky et al, 2003). At high intermittent dosing, hypersensitivity
reactions were encountered. Phase II trials are in progress.
PKI-166 (CGP59326)
This pyrrolo-pyrimidine, reversible, dual EGFR and erbB2 TKI is
under clinical development by Novartis and entered clinical trials
in 1999. PKI-166 has preclinical pharmacology typical of other
class compounds, with inhibition of epithelial tumour growth and
antiangiogenic actions (Baker et al, 2002), and the agent can
potentiate the activity of gemcitabine in preclinical models of
pancreatic cancer (Solorzano et al, 2001). In a phase I trial using a
2-week on/2-week off dosing schedule, dose-limiting skin rash and
diarrhoea was encountered at 900mg (Hoekstra et al, 2002). The
drug was found to be very well tolerated when administered three
times weekly (Murren et al, 2002).
GW-572016 (GW-2016)
GW-572016 (GW-2016), a 6-thiazolylquinazoline, is a reversible,
dual ErbB2 and EGFR TKI under development by GlaxoSmith-
Kline. Phase I data have recently been reported with notable
tumour responses seen in patients with trastuzumab refractory
breast cancer and in NSCLC (Spector et al, 2003). Inhibition of
phosphoAkt and inhibition of activated ERK1/2 in biopsies have
been linked with tumour regression.
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EKB-569, a 3-cyanoquinoline, is an irreversible, dual inhibitor of
EGFR and HER-2 tyrosine kinases. Phase I trials using both
intermittent and continuous dosing have shown the drug to be
generally well tolerated at doses up to the MTD of 75mgday
 1
(Hidalgo et al, 2002). Diarrhoea, skin rash, nausea, vomiting,
stomatitis and anorexia are the most frequently reported adverse
events. Phase II trials are currently underway.
ZD6474
ZD6474 is an orally bioavailable VEGFR flk-1/KDR receptor
(VEGFR-2) tyrosine kinase inhibitor of the quinazoline class.
This compound has additional activity against EGFR and fms-like
tyrosine kinase 4 (VEGFR3) (Ciardiello et al, 2003). Preclinical
data suggest that ZD6474 may have extended activity compared
to that seen with gefitinib (Matsumori et al, 2003). In keeping
with its EGFR inhibitory actions, skin rash has been commonly
encountered in phase I trials. Early phase II evaluation is in
progress.
EGFR TYROSINE KINASE INHIBITORS AND HORMO-
NAL THERAPY
Evidence suggests that, at least in preclinical models, cross-talk
between the oestrogen receptor (ER) and the EGF/HER2 receptor
pathways is associated with endocrine therapy resistance
(Nicholson et al, 2002). The treatment of wild-type MCF-7 breast
cancer cells with tamoxifen and gefitinib has been reported to
prevent development of tamoxifen resistance (Wakeling et al,
2001). The EGFR pathway may also play an important role in
oestrogen-independent breast cancer, and one group has
presented preclinical data suggesting that hormone independent
cells are more sensitive to EGFR TKIs than wild-type cells (Gee
et al, 2001). In xenografts of surgically removed DCIS breast
tissue, gefitinib has been found to reduce proliferation and
increase apoptosis, (Chan et al, 2000). The relevance of these
models to clinical settings of hormone resistance and DCIS needs
to be further tested.
RADIOTHERAPY AND EGFR TYROSINE KINASE IN-
HIBITORS
Tumour cell survival and repopulation following radiotherapy in
epithelial tumors may be regulated by the activation and
expression of EGFR and its ligands following radiation. Further-
more, the activation of downstream effectors of the EGFR
signalling pathway have been shown to increase cellular resistance
to ionizing radiation, suggesting that EGFR inhibitors may lead to
a reduction in tumour cell repopulation and the modulation of
cellular radiosensitivity (Harari and Huang, 2002). Additive to
synergistic interactions have been observed with in vitro and in
vivo studies of EGFR TKIs in combination with radiation; in some
instances there is sequence dependence something that should be
borne in mind in the clinical testing of these hypotheses.
CONCLUSIONS
Identification of the clinical activity of erlotinib and gefitinib in
NSCLC and SCCHN and the licensing of gefitinib for relapsed
NSCLC in Japan, Australia and USA have been important recent
developments in the field. New understanding of EGFR biology has
also emerged from clinical trials. There appears to be no simple
association between the level of EGFR1 expression and the clinical
activity of EGFR TKIs; high EGFR expressing tumours do not
constitute a group that is intrinsically more sensitive. The interplay
between EGFR expression, receptor activation, ligand expression,
levels of other EGFR members and downstream signalling proteins
needs to be defined by further research. Unlike the paradigm of
imatinib mesylate in gastrointestinal stromal tumours where
patients exhibit a relatively homogeneous phenotype, there seems
to be no easily identifiable human cancer phenotype with a strong
EGFR dependence. The results from phase II trials of gefitinib in
advanced recurrent NSCLC indicate that response seems to occur
more frequently in patients with adenocarcinoma than with
squamous carcinoma, but this observation requires confirmation
with other EGFR inhibitors.
Preclinical and clinical research should help in identifying
markers of EGFR TKI sensitivity and give pointers about
mechanisms of resistance to EGFR TKIs. Given the complex
interplay between EGFR family receptors it is not surprising that a
simple relationship between EGFR expression and sensitivity is
lacking. Evaluating downstream signalling components is more
likely to be helpful in identifying patients likely to benefit from
EGFR TKIs. Defining the mechanisms of resistance to EGFR
inhibitors coupled with identifying the clinical and molecular
profile of responding vs nonresponding patients in ongoing trials
remains an important priority and should hopefully enable a more
focused use of these drugs in future.
EGFR TKIs can sometimes produce remarkable and surprisingly
rapid tumour shrinkage and they have the potential to alter
tumour biology and the rate of tumour progression. Simply
defining a percentage response rate in phase II trials is a sub-
optimal approach to EGFR TKI development, and randomised
trials with end points such as time to progression, QOL, survival
are essential. Wherever possible, trials should be strengthened by
the study of pharmacodynmaics with a search for altered tumour
biology (proliferation, apoptosis, metabolism). Studies to date
have relied upon tumour or skin biopsies, but while these have
sometimes been used to guide subsequent trial design, they have
not resulted in the identification of a validated, predictive marker
for antitumour efficacy. Molecular imaging of pharmacodynamic
effects and visualisation of target inhibition is a promising area of
research that holds longer-term promise.
We urgently need a more comprehensive understanding of the
role of EGFR in human cancer. We must acknowledge that EGFR
receptor expression in a tumour does not prove that its function is
important for tumour growth, nor that inhibition will automati-
cally result in cell death or therapeutic effect. While the process of
clinically validating drug targets is notoriously difficult, EGFR
TKIs have relatively specific mechanisms of action, and advances
in pharmacodynamics, pharmacogenomics, and genomics/proteo-
mics must be applied in clinical settings to help us realise the full
potential of these agents.
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